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ABSTRACT
Tumor growth is not solely a consequence of autonomous tumor cell properties. 
Rather, tumor cells act upon and are acted upon by their microenvironment. It is 
tumor tissue biology that ultimately determines tumor growth. Thus, we developed a 
compound library screen for agents that could block essential tumor-promoting effects 
of the glioblastoma (GBM) perivascular stem cell niche (PVN). We modeled the PVN 
with three-dimensional primary cultures of human brain microvascular endothelial 
cells in Matrigel. We previously demonstrated stimulated growth of GBM cells in 
this PVN model and used this to assay PVN function. We screened the Microsource 
Spectrum Collection library for drugs that specifically blocked PVN function, without 
any direct effect on GBM cells themselves. Three candidate PVN-disrupting agents, 
Iridin, Tigogenin and Triacetylresveratrol (TAR), were identified and evaluated in 
secondary in vitro screens against a panel of primary GBM isolates as well as in two 
different in vivo intracranial models. Iridin and TAR significantly inhibited intracranial 
tumor growth and prolonged survival in these mouse models. Together these data 
identify Iridin and TAR as drugs with novel GBM tissue disrupting effects and validate 
the importance of preclinical screens designed to address tumor tissue function rather 
than the mechanisms of autonomous tumor cell growth.
INTRODUCTION
Despite decades of clinical and basic research, a 
diagnosis of glioblastoma (GBM) continues to carry a 
dismal prognosis, and new approaches to cure are needed. 
Recent studies have identified a sub-population of tumor 
cells with enhanced tumor-initiating capability, known 
as cancer “stem-like” cells (CSCs). CSCs are thought to 
drive tumor growth and recurrence [1-5], and therefore 
CSC-directed therapy may provide a long-awaited critical 
advance in GBM care. CSCs are localized to a specialized 
domain that surrounds the tumor microvasculature, often 
referred to as the peri-vascular niche (PVN). The PVN is 
a complex structure composed of tumor cells, microglia, 
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astrocytes, pericytes, and endothelial cells [6, 7]. Each 
component cell type may play a role in the maintenance 
of the CSC phenotype, thereby promoting tumor growth 
and therapeutic resistance [8-11]. Therefore, successful 
ablation of CSCs may be possible by targeting their 
interactions with these non-tumor cell components of the 
PVN. 
To better define the mechanisms by which 
endothelial cells drive GBM growth, and to provide 
a system for high throughput screening for drugs that 
can disrupt the functions of the PVN, we developed 
a co-culture system in which we could measure the 
tumor-promoting effects of endothelial cells on GBM 
cells [8]. In this model, primary cultures of human 
brain microvascular endothelial cells (HBMECs) and 
either an established human GBM cell line (U87) or 
primary GBM cell isolates were cultured together in a 
laminin-rich extracellular matrix (Matrigel). In Matrigel, 
HBMECs adopted a phenotype and spatial distribution 
reminiscent of endothelial cells in vivo. Addition of either 
primary GBM or U87 cells to the HBMECs resulted in 
migration of tumor cells to the PVN where they exhibited 
enhanced growth. A trophic effect of the PVN was 
mediated by endothelial cell-derived CXCL12 [8] and 
was blocked by treatment with the CXCR4 antagonist 
AMD3100, depletion of CXCL12 in endothelial cells or 
overexpression of G-protein coupled receptor kinase 3, a 
negative regulator of the CXCL12 receptor, CXCR4, in 
tumor cells [12]. These studies support the functionality 
of this model and its application in efforts to both identify 
pathways that mediate endothelial and GBM cell cross-
talk, and compounds that can target PVN function. We 
hypothesized that screens incorporating elements of this 
critical cell-cell interaction would have a higher likelihood 
of identifying agents with significant in vivo activity. 
A cell based high-throughput drug screen offers 
the potential to identify novel compounds that can be 
quickly moved to pre-clinical evaluation. Furthermore, 
examination of the targets of these lead compounds 
may reveal previously unappreciated biologic pathways 
contributing to GBM growth. We used our co-culture 
system to screen the Spectrum Collection compound 
library (Microsource Discovery Systems). This library 
contains a bio-diverse group of 2000 compounds including 
FDA approved drugs, compounds that are currently in 
clinical trials, experimental agents and natural extracts. 
Recent high-throughput screens of this library have 
identified potential novel anti-glioma therapeutics [13, 
14]. However, our screen is distinct from these prior 
studies as it measures anti-tumor cell effects in the setting 
of tumor-endothelial cell co-culture. Since endothelial 
cells can induce a treatment resistant and pro-growth state 
in tumor cells [15], we hypothesized that drugs that affect 
tumor cell growth in this more “native” microenvironment 
would have a greater chance of blocking tumor growth 
in vivo. Specifically, our current study was designed to 
identify drugs that inhibit glioma growth by disrupting the 
interaction between glioma and endothelial cells within 
the PVN rather than acting on tumor cells alone. 
RESULTS
Our previous studies demonstrated that an 
established GBM cell line, as well as tumor cells derived 
from primary pediatric GBM, showed enhanced growth 
when co-cultured with HBMECs in a laminin-rich 
Figure 1: Compound Library Screen Results: Two thousand compounds in the Spectrum Collection were screened 
for their efficacy in blocking the trophic effect of co-culture on luciferase-expressing U87 cell growth (% inhibition of 
trophic effect). Dotted line indicates three standard deviations above the mean effect. Compounds with inhibitory effects greater than 3 
SD above the mean are identified. Those compounds with both inhibitory effects greater than 3 SD above the mean and no direct cytotoxic 
effect are underlined.
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extracellular matrix [8]. This suggested that incorporation 
of these tumor microenvironmental elements would 
support a significantly more clinically relevant assessment 
of novel candidate anti-GBM agents. We used our co-
culture system to perform a high throughput compound 
library screen to identify novel compounds that could 
specifically block the trophic effects of endothelial cells on 
GBM cells. We designed the screen to rule out compounds 
that are simply cytotoxic to GBM cells and to identify 
those that are both non-toxic to tumor cells directly and 
potent antagonists of the trophic effect of the endothelia 
on tumor cell proliferation.
Primary screens
The initial screens were performed using a 
glioblastoma cell line (U87) stably expressing a GFP-
Luciferase construct in which U87 cell number has been 
demonstrated to be linearly related to bioluminescence 
(BLI) [16, 17]. Similar to our previous reports [8, 12], 
when cultured with HBMECs, U87 cells exhibited a ~2 
fold increase in tumor cell number as measured by BLI. 
When delivered at the compound library standard dose 
of 5μM, drug effects on HBMEC-stimulated U87 growth 
fell into four categories. The majority of compounds 
had no effect on U87 cells alone and did not block the 
trophic effect of endothelial cells on U87 cells (Figure 
1, Supplemental Figure 1). A second small group of 
compounds were generally cytotoxic to U87 cells alone 
and in co-culture. These were ruled out for further 
evaluation, as their anti-tumor effect was not specific to 
disrupting PVN function. A third interesting group was 
cytotoxic to U87 cells in monoculture, but not when U87 
cells were co-cultured. Based on the protective effects 
of the endothelial cells, this group of drugs, listed in 
Supplemental Table 1, would not likely exhibit in vivo 
anti-tumor activity, and these results highlight a pitfall of 
monoculture drug screening. The final class of drugs was 
a small but diverse group of compounds that had no effect 
on U87 monocultures but significantly blocked the trophic 
effects of HBMECs on U87 cells. Compounds with an 
anti-trophic effect of greater than three times the standard 
deviation of the mean library effect and without any direct 
cytotoxic effect were prioritized for additional evaluation 
(Table 1). Ten compounds met these criteria. Among them 
were two anthracycline anti-neoplastic agents, aklavine 
and mitoxanthrone. Interestingly, mitoxanthrone has 
recently been demonstrated to have efficacy in recurrent 
GBM [18, 19]. Also included were Dihydrodeoxygedunin, 
a member of a compound family with known neural 
differentiating activity [20] and both resveratrol and its 
derivative, Triacetylresveratrol. Resveratrol has garnered 
much attention as a potential anti-aging and anti-neoplastic 
agent [21-23].
Secondary screens
Only four compounds, Tigogenin, Iridin, 
Triacetylresveratrol (TAR) and Andirobin completely 
blocked the trophic effects of endothelial cells without any 
direct cytotoxic effects on the U87 cells. Therefore, these 
compounds were evaluated in secondary screens in which 
we sought first to first identify in vitro activity against a 
panel of primary adult and pediatric GBM specimens. 
These secondary screens were designed to directly test 
the dose responses to each compound in cell systems with 
greater fidelity to native GBM cell biology and with which 
we could capture the heterogeneity of GBM as it occurs 
in children and adults. We first determined whether the 
compounds might have toxicity against normal human 
astrocytes as this could limit their development as clinical 
agents. We treated primary human astrocyte cultures with 
Table 1: Candidate PVN disrupting agents
Compound   % Inhibition* Reported targets 
TIGOGENIN   100 p38 MAPK 
IRIDIN    100 Unknown activity 
TRIACETYLRESVERATROL  100 P53, Notch 
ANDIROBIN   100 Unknown activity 
MITOXANTHRONE HYDROCHLORIDE 96 Antineoplastic, Topo II inhibitor 
DIHYDROFISSINOLIDE  90 Unknown activity 
ADENINE    87 Vitamin B4  
RESVERATROL   87 Activates Notch-1, block Src/STAT3 
DIHYDRODEOXYGEDUNIN 83 Unknown activity 
AKLAVINE HYDROCHLORIDE  80 antibacterial, antineoplastic 
* The % inhibition of trophic effect by each compound was calculated as follows: %inhibition = [BLI (vehicle treated co-
culture) - BLI (drug-treated co-culture)]/ BLI (vehicle treated co-culture) - BLI (monoculture)] X 100
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Figure 2: Dose Response Curves for Lead Compounds in Primary GBM Cultures: Tigogenin, Iridin and TAR were 
each tested against a panel of primary GBM cultures (CDI-2, B18, G144, CDI-3). In each case, drug efficacy was measured 
by its ability to block the trophic effect of HBMEC conditioned media (CM). The basal trophic effect was measured as the fold-increase 
in cell number induced by CM (compare white to black bars). Cell number measured in CM cultures treated with a range of drug doses as 
indicated were normalized to cell number in equivalent drug treated TSM cultures. Shown are the means and SEM of three independent 
experiments.
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each drug (5 μM) and found that similar to their effects on 
U87 cells these compounds were non-toxic in monoculture 
(Supplemental Figure 2). As primary GBM cells did not 
contain luciferase, we could neither measure GBM cell 
number using BLI nor readily distinguish changes in 
GBM and endothelial cell number in physical co-culture. 
We therefore developed an alternate approach for assays 
of endothelial cell effect on primary GBM cell number 
involving primary GBM cell culture in media conditioned 
by HBMECs. In pilot studies, primary pediatric GBM 
cells (CDI-2, 3 and 4) were cultured in either standard 
tumorsphere media (TSM) or tumorsphere media 
conditioned by HBMECs for 96 hours. Cell numbers 
were measured using a cell proliferation kit (Promega). 
HBMEC conditioned media (CM) induced tumor cell 
growth to a similar extent (~2-5 fold) as physical co-
cultures with U87 cells and primary GBM cells as we 
previously reported (Supplemental Figure 3A) [8]. To 
determine whether there was any specificity in this growth 
effect for neoplastic cells, we measured growth of normal 
human astrocytes and found that HBMEC conditioned 
media had only a small effect on their growth (1.2 fold) 
suggesting some specificity of the HBMEC effect on GBM 
cells (Supplemental Figure 3B). These data indicated that 
factors secreted by HBMECs more potently stimulate 
GBM compared to astrocyte cell growth. Therefore, we 
performed initial secondary screens by treating tumor cells 
grown in CM in the presence or absence of the anti-trophic 
compounds. As a negative control we used melatonin, a 
compound that was completely inactive in the primary 
screen. 
Similar to their activity in the primary screen, 
none of the drugs had any direct effect on the tumor cells 
themselves but exhibited significant potency in blocking 
the trophic effect of the CM. The anti-trophic effects 
of the drugs were cell-type specific. Tigogenin, Iridin 
and TAR successfully blocked the trophic effect of CM 
on CDI-2 cells and had a partial effect on CDI-4 cells, 
but were completely ineffective with the CDI-3 cells 
(Supplemental Figure 3A). Andirobin was ineffective 
at blocking the trophic effects of CM on any of these 
primary GBM specimens (data not shown). These results 
suggest that Andirobin may block a contact-mediated, 
rather than a secreted factor-mediated, effect of ECs on 
GBM cell growth. We recently reported induction of 
phosphodiesterase 7B in GBM tumor cells through direct 
contact-mediated effects of endothelial cells in this same 
co-culture model [24]. Andirobin was not further evaluated 
in these studies. Together, these results emphasize the 
importance of multiple cell line testing to address the 
highly heterogeneous nature of GBM. In line with our 
observations from the initial screens, melatonin had no 
effect on primary GBM cells in the secondary screen.
To determine the optimal doses for the anti-
trophic effect of these compounds, we performed dose 
response studies for Tigogenin, Iridin and TAR on the 
pediatric GBM cell lines CDI-2 and CDI-3, as well as 
two additional primary adult GBM derived stem cell 
lines, G144 and B18 (Figure 2). We tested the anti-trophic 
activity of these drugs at doses ranging from 0.05μM to 
500 μM. Tigogenin and Iridin displayed reproducible 
dose responses in the CDI-2, G144 and B18 cells with 
maximal inhibition at 500 μM. Triacetylresveratrol had 
a similar dose response in the CDI-2 cells but exerted a 
general inhibition at most concentrations in G144 and B18 
cells. Consistent with the pilot studies, none of the drugs 
Figure 3: Iridin and TAR have significant in vivo anti-tumor effects: A. Median survival in mice bearing intracranial xenografts 
of U87 cells was significantly prolonged by Iridin treatment. Median survival trended towards prolongation in Triacetyresveratrol (TAR) 
treated mice but was unaffected by Tigogenin treatment. P values were determined by Log-Rank test of Kaplan-Meier plot. B. Intracranial 
growth of luciferase-expressing G144 xenografts was followed by bioluminescence imaging (BLI) every other week. Shown are the mean 
+/- SEM BLI as a function of weeks post tumor implantation for three treatment groups (Vehicle, TAR-treated and Iridin-treated). Means 
were calculated by first normalizing each BLI measurement to the first BLI measurement for each mouse individually and then averaging 
the normalized BLIs for each treatment group. Initiation of treatment at week 14 is indicated by the arrow. Significance was determined by 
two-way ANOVA.
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showed any anti-trophic effect on CDI-3 cell proliferation. 
In primary human astrocytes, only Triacetylresveratrol 
demonstrated inhibition of the modest tropic effect of 
CM (Supplemental Figure 3C). These data confirmed 
the potential importance of these three compounds as 
candidate anti-GBM agents and also indicated that they 
exert their effects directly on tumor cells, but only when 
these tumor cells are sensitized through the actions of 
endothelial cell-derived secreted factors.
Effect of compounds on HBMECs
In the primary physical co-culture screens, both 
tumor cells and endothelial cells were exposed to the 
anti-trophic compounds, but only the proliferation of 
tumor cells was assessed. To directly assess the effect 
of compounds on HBMECs, HBMECs were cultured 
with drugs at concentrations of 0.05-50 µM for 4 days 
(Supplemental Figure 4). Iridin and Tigogenin increased 
HBMEC proliferation by 30-40% at concentrations at 
or above 5 µM for Iridin and 50 µM for Tigogenin. In 
the primary screen (drug concentrations of 5 uM), Iridin 
and Tigogenin diminished the trophic effect of HBMECs 
on GBM cells, despite the possible increase in HBMEC 
cell number. At the dose used in primary screens (5 uM), 
HBMEC cell number was diminished by TAR by 35%. 
Therefore, the direct toxicity of TAR on HBMECs may 
account for some of the anti-trophic effect of that drug 
in the co-culture model of the primary screen. However, 
in the secondary screens, the experimental paradigm does 
not subject HBMECs to anti-trophic compounds, as the 
compounds are added to media conditioned by untreated 
HBMECs. Therefore, while the direct toxicity of TAR 
on HBMECs may account for some of its anti-trophic 
effect on tumor cell growth in the primary screen, the 
secondary screen demonstrates that TAR is also effective 
in diminishing the HBMEC trophic effect caused by direct 
action on tumor cells.
Pre-clinical evaluation of lead compounds
The ultimate goal of these studies is the identification 
of PVN-disrupting drugs for clinical evaluation. Thus, 
the anti-tumor effects of Tigogenin, Iridin and TAR were 
further evaluated using intracranial xenograft models of 
GBM as previously described by us and others [8, 25]. An 
initial in vivo screen was performed with U87 cells. As is 
standard in our model, 50,000 firefly luciferase-expressing 
tumor cells were stereotactically implanted into the cortex 
of nude mice. Engraftment and initial growth were verified 
by weekly bioluminescence imaging (BLI), and those 
mice with tumors exhibiting equivalent rates of growth 
were randomized into four treatment groups: 1) vehicle 
control, 2) Tigogenin, 3) Iridin and 4) TAR. Each drug 
was delivered by oral gavage at 20 mg/kg daily for 5 days 
each week. Compared to vehicle treated controls, Iridin 
treatment resulted in a statistically significant prolongation 
of median survival from 15 to 22 days (p = 0.0027, log-
rank test) (Figure 3A). TAR treatment trended towards 
a similar survival benefit with a shift in median survival 
from 15 to 19 days (p = 0.07, log-rank test) compared to 
control. In this model, Tigogenin was without effect. 
To further evaluate the potential therapeutic value 
of Iridin and TAR, we treated mice bearing intracranial 
xenografts of the primary G144 GBM isolate engineered 
to express firefly luciferase. After establishing engraftment 
and steady tumor growth (14 weeks post implantation), 
mice were randomized to three treatment groups: 1) 
vehicle, 2) Iridin and 3) TAR. Treatment was the same 
as for the U87 experiment, and intracranial growth was 
followed with bi-weekly bioluminescence imaging. Both 
Iridin and TAR rapidly and significantly blocked further 
intracranial growth (Figure 3B). 
DISCUSSION
Despite decades of research, median survival for 
GBM remains relatively unchanged. Novel therapeutics 
and approaches are needed. While reports of new drugs 
with promising activity are frequent, few gains have 
been observed in the clinic. Among the reasons for the 
disappointing performance of standard preclinical studies 
may be the common format for drug screening in which 
novel compounds are tested against panels of tumor cell 
monocultures to identify agents that can block tumor cell 
autonomous mechanisms of growth. GBM, like other solid 
cancers, are highly complex tissues in which cell-cell 
interactions drive tumor growth and promote resistance 
[6]. Thus, we reasoned that a screen for compounds that 
blocked these cell-cell interactions would enhance the 
specificity for drugs that could function in vivo, within 
the context of tumor tissue, and thereby improve the 
translational potential of any results. 
To prove the utility of this approach, we 
purposefully focused on agents that had no direct 
cytotoxic effect and whose in vitro activity was confined 
to blockade of endothelial cell stimulated growth. We 
screened the Spectrum Collection because among the 2000 
compounds in this library are many naturally occurring 
and FDA approved drugs and therefore there is potential 
for rapid translation. Several of the compounds were 
generally toxic and killed tumor cells grown alone or as 
co-cultures, some were toxic in monocultures but had no 
effect in the presence of endothelial cells, and only a few 
were capable of specifically blocking the trophic effect ( > 
3 SD of the mean) of endothelial cells on the GBM cells. 
These observations, particularly those instances where 
drugs were cytotoxic in tumor cell monocultures but not in 
the co-cultures, highlight the importance of the co-culture 
and HBMEC-conditioned media models for this screen. 
Treating tumor cells alone would have identified drugs 
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with less translational potential. 
Iridin, Tigogenin and TAR are all non-cytotoxic 
compounds derived from naturally occurring plant 
sources. Iridin is a glucoside found in both the rhizomes 
of the iris plant such as Iris versicolor, and the roots of 
violets. It is more commonly known as Blue Flag and 
has historically been used for “removing bile” and as a 
laxative. Multiple compounds derived from the Iridaceae 
family have been evaluated for their anti-tumor and 
anti-inflammatory effects [26]. Liu et al. showed that 
several have an anti-tumor effects on various cancer 
cell lines including stomach cancer, breast cancer, and 
prostate cancer [27]. Interestingly, Iridin did not exhibit a 
substantial anti-tumor effect in these monoculture assays, 
again underscoring the importance of drug screening in a 
co-culture system. It was only in this setting that Iridin’s 
anti-tumor effect was revealed. 
TAR is a derivative of Resveratrol with improved 
bioavailability [28]. Resveratrol has gained media 
attention for its potential anti-aging and anti-cancer effect. 
It was first discovered in 1937 in the roots of Japanese 
Knotweed, but it can also be derived from grape skins 
leading some to investigate its role in the health benefits 
seen from drinking red wine [29, 30]. Although anti-
aging effects have not been consistently reproducible, 
it has been shown to have anti-inflammatory and blood 
sugar lowering effects [29, 30]. It has been evaluated 
in clinical trials for type 2 diabetes, Alzheimer’s 
disease, cardiovascular disease, obesity, inflammation, 
concussions, and polycystic ovarian syndrome. Several 
studies have also indicated that Resveratrol may inhibit 
events associated with tumor formation and progression 
[31, 32]. Mgbonyebi et al. reported that Resveratrol 
inhibited the proliferation of human breast epithelial 
cells in a dose-dependent manner. Jang et al. showed 
that Resveratrol had anti-initiation, anti-promotion and 
anti-progression activity against human promyleocytic 
leukemia cells. Piceatonnol, a natural metabolite of 
Resveratrol, has also been shown to enhance cisplatin-
induced apotosis, making it an attractive modulator for 
treatment of many cancers, especially ovarian cancer, 
which is often resistant to cisplatin [33]. Interestingly, 
Resveratrol has also been shown to decrease cell growth 
through inhibition of Notch 1 signaling [34], a pathway 
that has been shown to be important in growth of GBM 
and proliferation of GBM stem-like cells within the PVN 
[35]. These studies have led to clinical trial investigations 
in several malignancies such as gastrointestinal tumors, 
colon cancer, and multiple myeloma [36]. Resveratrol is 
readily available, making it an attractive therapeutic for a 
clinical trial in patients with GBM. 
These studies suggest that the mechanisms of 
tumor cell expansion within tumor tissue can be distinct 
from the mechanisms that drive tumor cell expansion 
in monoculture. Thus, TAR and Iridin blocked U87 and 
primary GBM isolate growth in co-culture and in vivo but 
were without effect in monoculture. Rigorous elucidation 
of their mechanisms of action will be key to the continued 
development of these agents. This will include both the 
definition of their cellular targets and their intracellular 
target pathways. We tested the effect of each compound 
on both normal human astrocytes and HBMECs and 
found that only TAR exhibited any cytotoxicity and this 
effect was limited to HBMECs. In addition TAR was able 
to block the modest trophic effect of CM on astrocytes. 
Together these data suggest that the drugs are working 
primarily on GBM cells. Further elucidation of their target 
pathways is likely to advance our understanding of PVN 
biology and identify new therapeutic targets. 
Finally, these results suggest that contextualized 
GBM cell growth carries specific vulnerabilities for 
tumor cells. It may be necessary to screen in this “tumor 
tissue” context to fully capitalize on the vast numbers 
of synthesized and available compounds before we can 
achieve significant improvements in the treatment of GBM 
and other intractable cancers. The data reported in this 
study directly supports this conclusion. Moreover, our data 
indicate that both Iridin and TAR are viable candidates for 
novel clinical trials designed to disrupt the function of the 
PVN. Particularly important may be the combination of 




All animals were used in accordance with an Animal 
Studies Protocol (# 20120174) approved by the Animal 
Studies Committee of the Washington University School 
of Medicine per the recommendations of the Guide for the 
Care and Use of Laboratory Animals (National Institutes 
of Health). 
Human studies
Primary human GBM specimens for culture were 
obtained and utilized in accordance with a Washington 
University Institutional Review Board (IRB)-approved 
Human Studies Protocol (#201102299). 
Cell culture
Primary human GBM (CDI) cells
Fresh brain tumor resection material from pediatric 
glioblastoma patients was obtained according to a 
Washington University School of Medicine IRB approved 
human studies protocol. Resection material was minced 
into small pieces using sterile scalpels and dissociated 
in Accutase at 37°C. Single cells were obtained and 
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cultured in tumor sphere media (TSM), which contains 
Neurobasal-A media (Gibco) supplemented with 
Glutamax (Gibco), 20 ng/mL epithelial growth factor 
(EGF, Sigma), 20 ng/mL basic fibroblastic growth factor 
(bFGF, Chemicon), 20 ng/mL leukemia inhibitory factor 
(LIF, Chemicon), 1 x N2 Supplement (Gibco), 1 x B-27 
Serum-Free Supplement (Gibco), and heparin (20 ug/mL, 
Sigma). Cells were initially plated on tissue-culture coated 
plates overnight to allow non-stem-like cells to attach, 
and the non-adherent stem-like cells were transferred to 
extracellular matrix protein (ECM)-coated tissue culture 
plates prepared by coating with 10% ECM (Sigma) in 
Hanks Buffered Saline Solution (HBSS) and washed 
three times in HBSS. Thereafter, GBM stem cells were 
maintained in adherent culture on ECM-coated plates in 
TSM media, which was changed every 2 to 3 days.
B18 and G144 cells
Primary GBM cell lines were created from freshly 
isolated tumor resection tissue as previously described 
[37]. Briefly, primary GBM tumor tissue was cleaned 
manually of RBCs, mechanically dissociated with forceps 
and scalpel, and chemically dissociated with Accutase 
(Sigma). Cells were then spun down and triturated gently. 
Cells were then plated on PLO (Sigma) and Laminin 
(Sigma) coated Primaria plates (BD Biosciences). Cells 
were used for experiments after the fifth passage. Media is 
RHB-A with EGF (10ng/mL) and FGF (10ng/mL).
Primary human endothelial cells
Primary human brain microvascular endothelial 
cells (HBMEC) were obtained from ScienCell, Carlsbad, 
CA. HBMECs were used between passages 3-8 and 
maintained in endothelial cell growth media (EGM-2MV 
(Lonza, Basel, Switzerland)) on gelatin-coated dishes. 
Primary human astrocytes
Primary normal human astrocytes (NHAs) were 
obtained from Lonza. NHAs were used between passages 
3-8 and maintained in astrocyte growth media (EGM 
BulletKit (Lonza)) on Primaria plates. 
Established human GBM cell line
U87 cells were originally obtained from ATCC and 
were engineered at low passage ( < 5) to express a fusion 
protein of firefly luciferase and enhanced green fluorescent 
protein (eGFP) driven by the human ubiquitin C promoter 
after transduction with a lentivirus (FUW-FLG) as 
described previously [38-40]. U87 cells expressing firefly 
luciferase-eGFP (U87-Luc) were sorted to purity based 
on GFP expression, expanded and stored at -150 degrees 
Celsius. All experiments were performed with U87-Luc 
cells at less than passage 15 approximately 4 months post 
acquisition from ATCC. U87 cells were maintained in 
DMEM supplemented with 10% fetal bovine serum.
GBM - endothelial cell co-cultures and high 
throughput screening
Human brain microvascular endothelial cells were 
plated (3000 cells/well) within an extracellular matrix 
(Matrigel, BD Dickinson) in 96-well plates compatible 
with bioluminescent measurement. After 24 hours (to 
allow for endothelial cell tubule formation), U87 cells 
(3000 cells/well) were added to the assay plates in 
minimal essential media as previously described [8]. 
Compounds from the Spectrum Collection (Microsource 
Discovery Inc.) were added to the co-cultures as well as to 
monocultures of tumor cells. DMSO vehicle treated wells 
at the same concentration as the diluted solvent in the 
library wells served as controls for each plate tested. The 
library consisted of FDA approved drugs (50%), natural 
products (30%) other non-drug bio-active compounds 
(20%). The compounds were supplied as 10mM solutions 
in DMSO and were used at a final concentration of 5µM 
for the assay. Each compound was tested in triplicate. 
Hence for each compound plate, we had six experimental 
(three tumor monoculture and three co-culture) plates. 
The High Throughput Screening Core at the Washington 
University School of Medicine was used for the screen. 
Cell numbers were assessed by BLI after 2 days in co-
culture. The numbers of metabolically active tumor 
cells were determined by measuring luminescence upon 
addition of the substrate luciferin to the 96 well plates. 
The trophic effect was determined as the ratio of the mean 
of the bioluminescence reading from the co-cultures to 
that of the monocultures for vehicle treated wells. The 
% inhibition of trophic effect by each compound was 
calculated as follows: %inhibition = [BLI (vehicle treated 
co-culture) - BLI (drug-treated co-culture)]/ BLI (vehicle 
treated co-culture) - BLI (monoculture)] X 100.
Preparation of HBMEC conditioned media
Secondary screens
Primary GBM specimens or NHAs were cultured 
in ECM (Sigma) coated 96 well plates in either TSM or 
HBMEC conditioned media in the absence or presence of 
compounds. HBMEC conditioned media was generated 
daily by incubating an equivalent number of HBMECs 
with TSM overnight. After harvest of conditioned media, 
Iridin, Tigogenin, or TAR were added at concentrations 
from 0.05 µM to 500 µM. Media was changed daily for 
4 days. After 4 days, cell proliferation was determined 
by the CellTiter 96 Aqueous One Cell proliferation Assay 
System following the manufacturer’s protocol (Promega, 
Madison, WI). Absorbance at 490 nm was measured using 
the µQuant microplate Reader (Bio-Tek instruments, 
Winooski, VT). Absorbances from culture medium 
and CellTiter 96 Aqueous One Solution reagent served as 
Oncotarget18290www.impactjournals.com/oncotarget
background.
Generation of intracranial xenografts
Intracranial xenografts were generated as previously 
described [16, 17, 40]. Tumor cell lines were harvested 
in mid-logarithmic growth phase and resuspended in 
PBS. Homozygous NCR female nude mice (Taconic 
Farms, Germantown, NY) were anesthetized with 
ketamine hydrochloride at 150 mg/kg and xylazine at 12 
mg/kg (Phoenix Pharmaceuticals, St Joseph, MO) via 
intraperitoneal (i.p.) injection. The cranium was exposed, 
and a small hole was made with a size 34 inverted cone 
burr (Roboz, Githersburg, MD). Mice were fixed in a 
stereotactic frame (Stoelting, Wood Dal, IL), and cells 
were injected through a 27-gauge needle over 2 minutes at 
2mm lateral and posterior to the bregma and 3mm below 
the dura (50,000 U87 cells in 7.5uL of PBS or 94,200 
G144 primary cells in 6 uL of media). The incision was 
closed with Vetbond (3M, St. Paul, MN). 
Bioluminescence imaging
Bioluminescence imaging of intracranial 
xenografts was performed as previously described [16, 
40]. NCR nude mice bearing intracranial xenografts of 
U87-luc cells were injected with 150 ug/g D-luciferin 
(Biosynth) in PBS, anesthetized with 2.5% isoflurance 
and imaged with a charge-coupled device camera-based 
bioluminescence imaging system (IVIS 50; Perin-Elmer, 
Waltham, MA; exposure time = 1-60 s, binning = 8, 
field of view = 12, f/stop = 1, open filter). Signals were 
displayed as photons/s/cm2/sr. Regions of interest were 
defined manually at 95% of the maximum pixel output 
using Living Image an IgorPro Software (v 2.50) and 
data were expressed as total photon flux (photons per 
second). Generally, the first mouse images were obtained 
3-5 days following intracranial inoculation of the tumor 
cells then weekly. Data were analyzed and plotted as the 
ratio of bioluminescence on a given treatment day over 
bioluminescence on the first day. 
In vivo Drug Treatment
Mice bearing U87 intracranial xenografts were 
imaged twice after implantation to identify those with 
equivalent tumor growth rates. Two weeks after tumor 
cell implantation, cohorts of mice with approximately 
equivalent tumor bioluminescence were divided into 
equal control and treatment groups (5-6 mice per group). 
Mice bearing primary G144 xenografts were imaged 
every other week for three months to establish equivalent 
and continuous rates of growth. Systemic therapies: 
Tigogenin, Iridin, TAR (Microsource Discovery Systems), 
or vehicle was administered daily Monday through Friday 
(20mg/kg) by gavage. Drugs were resuspended in 0.5% 
carboxymethyl cellulose (CMC).
Statistical analysis
Data were analyzed using GraphPad Prism version 
4.00 (GraphPad Software). Kaplan-Meier survival curves 
were analyzed using pairwise log-rank tests. Given 
the repeated measurement of mice over time, statistical 
differences in growth curves were analyzed using the 
generalized estimating equation regression analysis. 
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